Who makes Lyumjev U-100 Insulin?

Lyumjev U-100 Insulin is developed by Portal Diabetes, Inc..

What development phase is Lyumjev U-100 Insulin in?

Lyumjev U-100 Insulin is in Phase 1.

Last reviewed 2026-04-19 · How we verify

Lyumjev U-100 Insulin

Portal Diabetes, Inc. · Phase 1 active Small molecule

At a glance

Generic name	Lyumjev U-100 Insulin
Sponsor	Portal Diabetes, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Single Bolus, 12-hour Euglycemic Clamp Study of the Safety, Pharmacokinetics (PK) and Glucodynamics (GD) of Intraperitoneal (IP) Portal Insulin U-500 (PHASE1)
Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Lyumjev U-100 Insulin CI brief — competitive landscape report
Lyumjev U-100 Insulin updates RSS · CI watch RSS
Portal Diabetes, Inc. portfolio CI